0000000000660764

AUTHOR

Mirko Nitsche

showing 3 related works from this author

Chemoradioimmunotherapy with 5-fluorouracil, cisplatin and interferon-α in pancreatic and periampullary cancer: Results of a feasibility study

2008

Abstract Background Recent studies give rise to the hypothesis, that adjuvant chemoradioimmunotherapy with 5-fluorouracil (5-FU), cisplatin and interferon-α (IFN-α) might be a possible new treatment of pancreatic cancer in resected patients. We report the up-to-now experience at our institution. Patients and methods Eleven patients with histological diagnosis of localized carcinoma of the pancreas ( n  = 7) or periampullary ( n  = 4) were prospectively analyzed. Four patients were deemed unresectable because of local invasion of adjacent organs (neoadjuvant setting) and seven patients underwent curative resection (adjuvant setting). Eight patients were classified as T3 carcinomas and three …

Malemedicine.medical_specialtyPancreatic diseasemedicine.medical_treatmentAntineoplastic AgentsRisk AssessmentGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancermedicinePeriampullary cancerHumansNeoplasm InvasivenessRadiology Nuclear Medicine and imagingSurvival rateNeoplasm Staging030304 developmental biology0303 health sciencesbusiness.industryPatient SelectionRadiotherapy Dosagemedicine.diseaseCombined Modality Therapypeople.cause_of_deathRecombinant Proteins3. Good healthSurgeryPancreatic NeoplasmsSurvival RateRadiation therapyOncology030220 oncology & carcinogenesisConcomitantInterferon Type IFeasibility StudiesFemaleFluorouracilImmunotherapyCisplatinbusinesspeopleChemoradiotherapyProgressive diseaseCancer/Radiothérapie
researchProduct

Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study

2011

Abstract Background and purpose Fludarabine is an adenine nucleoside analogue that has significant activity in hematological malignancies and has shown promising activity in combination with radiation in preclinical solid tumor models. We designed a phase I trial exploring concurrent fludarabine and radiotherapy in patients with advanced non-small cell lung cancer (NSCLC) to determine the maximum tolerated dose (MTD) of fludarabine given with concurrent irradiation. Materials and methods Thirteen patients with stage IIIB NSCLC received thoracic irradiation of 60 Gy. Fludarabine was administered during the 5th and 6th week of radiotherapy. Doses started at 10 mg/m2 per day and increased by s…

Oncologymedicine.medical_specialtyCancer ResearchRadiation-Sensitizing AgentsLung Neoplasmsmedicine.medical_treatmentAntineoplastic AgentsNSCLCMedicine & Public Health; Hematology; Oncology; Internal Medicine; Cancer Research03 medical and health sciencesFludarabine0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungCarcinomaMedicineCombined Modality TherapyHumansConcurrent fludarabine and radiotherapy030304 developmental biologyNeoplasm Staging0303 health sciencesOriginal PaperHematologyNucleoside analoguebusiness.industryRadiotherapy DosageGeneral MedicineAdenine nucleosideRadiochemotherapy in stage III NSCLC locally advanced inoperable NSCLCNucleoside analoguemedicine.diseaseCombined Modality Therapy3. Good healthFludarabinerespiratory tract diseasesClinical trialRadiation therapyOncology030220 oncology & carcinogenesisRadiotherapy phase I studybusinessFludarabine; NSCLC; Nucleoside analogue; Concurrent fludarabine and radiotherapy; Radiotherapy phase I study; Radiochemotherapy in stage III NSCLC locally advanced inoperable NSCLCVidarabinemedicine.drug
researchProduct

The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro.

2008

Despite proven antitumor activity of gemcitabine in chemoradiotherapy of advanced head and neck cancer, many authors refer to severe acute and late local and haematological toxicity. Fludarabine does imply nearly the same mechanisms of action as gemcitabine, inhibiting various enzymes involved in DNA replication. This investigation focuses on the combined effect of either fludarabine or gemcitabine and radiation on human squamous carcinoma cell lines in vitro, providing data for future decisions on head and neck chemoradiotherapy regimen.ZMK-1, A549, BW-225, GR-145, OH-65 and CaSki cell lines were incubated with either drug at defined schedules and irradiated at a single fraction dose of 2 …

Oncologymedicine.medical_specialtyRadiation-Sensitizing AgentsCell SurvivalApoptosisDeoxycytidine03 medical and health sciences0302 clinical medicineFludarabine monophosphateInternal medicineCell Line TumormedicineCarcinomaHumansRadiology Nuclear Medicine and imaging030304 developmental biology0303 health sciencesRadiological and Ultrasound Technologybusiness.industryHead and neck cancermedicine.diseaseGemcitabineGemcitabine3. Good healthFludarabineSquamous carcinomaApoptosis030220 oncology & carcinogenesisCarcinoma Squamous CellbusinessVidarabine PhosphateChemoradiotherapymedicine.drugInternational journal of radiation biology
researchProduct